Abstract

Introduction Trichosporon asahii is a yeast-like basidiomycete that can cause infections in immunocompromised hosts including superficial infections, pneumonia, meningitis, fungemia, and disseminated trichosporonosis. These infections have become more common over the last 30 years in patients with burns or other immunosuppressive conditions. Disseminated T. asahii is intrinsically difficult to treat and carries a mortality rate as high as 70% despite the availability of effective medications.MethodsA 61-year-old male was admitted after falling into a vat of pig manure which was 160 degrees F, resulting in approximately 75% total body surface area injury to his anterior and posterior trunk, and bilateral upper and lower extremities. Throughout his hospital course, he underwent surgical debridement on multiple occasions with placement of homograft, autograft, and spray keratinocytes. The earliest cultures to demonstrate T. asahii growth were obtained on post-burn day (PBD) 23 and growth continued until PBD 32. Quantitative colony counts ranged from 600-365000000 CFU/g from left lower and upper extremities and chest. Cultures were obtained in preparation for cultured epithelial autograft placement which occurred on PBD 36. Susceptibility testing was sent and the minimum inhibitory concentration (MIC) results are reported in Table 1. Clinical and Laboratory Standards Institute (CLSI) guidelines for interpretation of susceptibility are not available for T. asahii, but suggested breakpoints are summarized in Table 1.ResultsOn PBD 23, topical amphotericin B irrigation and voriconazole oral suspension were initiated. A voriconazole level was obtained on PBD 31, which was subtherapeutic, and dosing was subsequently adjusted. In total, the patient received 13 days of topical amphotericin B and 21 days of voriconazole for treatment. Subsequent cultures demonstrated microbiologic cure of T. asahii.ConclusionsThis immunocompromised burn patient was successfully treated for Trichosporon asahii using a combination of topical and systemic antifungal agents.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.